(Q22242395)

7 February 2023

9

B. Winblad

B

Winblad

1 reference

7 February 2023

G. Waldemar

1

G

Waldemar

1 reference

7 February 2023

B. Dubois

2

B

Dubois

1 reference

7 February 2023

M. Emre

3

M

Emre

1 reference

7 February 2023

J. Georges

4

J

Georges

1 reference

7 February 2023

I. G. McKeith

5

I G

McKeith

1 reference

7 February 2023

P. Scheltens

7

P

Scheltens

1 reference

7 February 2023

P. Tariska

8

P

Tariska

1 reference

European Journal of Neurology

7 February 2023

language of work or name

English

0 references

publication date

January 2007

0 references

published in

0 references

volume

14

0 references

issue

1

0 references

page(s)

e1-e26

0 references

1 reference

https://api.crossref.org/works/10.1111/J.1468-1331.2006.01605.X

A systematic review of the effectiveness of psychosocial interventions for carers of people with dementia

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1468-1331.2006.01605.X

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The Decreasing Prevalence of Reversible Dementias

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Electroencephalography as an aid in the exclusion of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Reliability of the Washington University Road Test. A performance-based assessment for drivers with dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Estrogen levels do not correlate with improvement in cognition

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Frequency oftau mutations in three series of non-Alzheimer's degenerative dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Clinical utility of computed tomography in the assessment of dementia: a memory clinic study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Diagnosis and management of normal-pressure hydrocephalus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A modified card sorting test sensitive to frontal lobe defects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Early marker for Alzheimer's disease: the atrophic hippocampus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Improving screening accuracy for dementia in a community sample by augmenting cognitive testing with informant report.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The diagnostic value of electroencephalography in mild senile Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Behavioural changes and psychological symptoms in dementia disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The diagnosis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Screening for dementia: a preliminary study on the validity of the Chinese version of the Blessed-Roth Dementia Scale

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Donepezil in the treatment of progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Meta-analysis of psychosocial interventions for caregivers of people with dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Studies of interference in serial verbal reactions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The burden of brain diseases in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Effects of aging and of Alzheimer's disease on verbal memory

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

How to improve the clinical diagnosis of Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Measurement of functional activities in older adults in the community.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A comprehensive support program: effect on depression in spouse-caregivers of AD patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

How effective are interventions with caregivers? An updated meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The 1994 International Consensus Conference on Dementia and Driving: a brief report. Swedish National Road Administration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Volumetric and visual assessment of the mesial temporal structures in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004*

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Cost of dementia in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Donepezil treatment of vascular dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Genetic testing for Huntington's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Treating behavioural and psychological signs in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Transient epileptic amnesia: a description of the clinical and neuropsychological features in 10 cases and a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Potentially reversible conditions in 1000 consecutive memory clinic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Alzheimer disease: operating characteristics of PET--a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Corticobasal degeneration: evaluation of cortical atrophy by means of hemispheric surface display generated with MR images.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Health and relicensing policies for older drivers in the European union

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

New approaches to clinical trials in vascular dementia: memantine in small vessel disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Association between statin use and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Combining cognitive testing and informant report to increase accuracy in screening for dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

An examination of self-reported chronic conditions and health status in the 2001 Medicare Health Outcomes Survey

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Manchester and Oxford Universities Scale for the Psychopathological Assessment of Dementia (MOUSEPAD).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Donepezil in vascular dementia: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

EEG abnormalities in frontotemporal lobar degeneration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) as a screening tool for dementia for a predominantly illiterate Chinese population.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The spectrum of behavioral changes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Testing cognition may contribute to the diagnosis of movement disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Screening for dementia with the memory impairment screen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Medial temporal lobe atrophy on MRI in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Practice parameter: risk of driving and Alzheimer's disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Rates of global and regional cerebral atrophy in AD and frontotemporal dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Epilepsy presenting as AD: neuroimaging, electroclinical features, and response to treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Diagnostic strategies in CADASIL

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Validity of the Trail Making Test as an Indicator of Organic Brain Damage

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

The use of memantine in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Frontotemporal Dementia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01605.X

7 January 2021